ABSTRACT

Introduction

Drug-eluting embolic (DEE) microspheres, or drug-eluting beads (DEB), delivered by transarterial chemoembolization (TACE) serve as a therapeutic embolic to stop blood flow to tumors and a drug delivery vehicle. New combinations of drugs and DEE microspheres may exploit the potential synergy between mechanisms of drug activity and local tissue responses generated by TACE to enhance the efficacy of this mainstay therapy.

Areas covered

This review provides an overview of key drug delivery concepts related to DEE microspheres with a focus on recent technological developments and promising emerging clinical applications as well as speculation into the future.

Expert opinion

TACE has been performed for nearly four decades by injecting chemotherapy drugs into the arterial supply of tumors while simultaneously cutting off their blood supply, trying to starve and kill cancer cells, with varying degrees of success. The practice has evolved over the decades but has yet to fulfill the promise of truly personalized therapies envisioned through rational selection of drugs and real-time multi-parametric image guidance to target tumor clonality or heterogeneity. Recent technologic and pharmacologic developments have opened the door for potentially groundbreaking advances in how TACE with DEE microspheres is performed with the goal of achieving advancements that benefit patients.

中文翻译：

---

药物洗脱栓塞微球：最先进和新兴的临床应用

 抽象的

 介绍

通过经动脉化疗栓塞 (TACE) 递送的药物洗脱栓塞 (DEE) 微球或药物洗脱珠 (DEB) 可用作阻止血液流向肿瘤的治疗性栓塞和药物递送载体。药物和 DEE 微球的新组合可能会利用药物活性机制与 TACE 产生的局部组织反应之间的潜在协同作用，以增强这一主要疗法的功效。

 覆盖领域

本综述概述了与 DEE 微球相关的关键药物输送概念，重点关注最新的技术发展和有前景的新兴临床应用以及对未来的推测。

 专家意见

TACE 已经进行了近四十年，通过将化疗药物注射到肿瘤的动脉供应中，同时切断其血液供应，试图饥饿和杀死癌细胞，并取得了不同程度的成功。这种做法已经发展了几十年，但尚未实现通过合理选择药物和实时多参数图像指导来靶向肿瘤克隆性或异质性而设想的真正个性化治疗的承诺。最近的技术和药理学发展为如何使用 DEE 微球进行 TACE 的潜在突破性进展打开了大门，以实现造福患者的进步。